Levetiracetam Solution

Levetiracetam Solution Manufacturers

• Pharmaceutical Associates, Inc.
  

  ×

  Levetiracetam Solution | Pharmaceutical Associates, Inc.

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam Oral Solution USP is given orally with or without food. The Levetiracetam Oral Solution USP dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight less than or equal to 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Dosing for Partial Onset Seizures

  Adults 16 Years and Older

  Initiate treatment with a daily dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1,000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3,000 mg. There is no evidence that doses greater than 3,000 mg/day confer additional benefit.

  Pediatric Patients

  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.'s levetiracetam oral solution. However, due to UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  4 Years to less than 16 Years

  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3,000 mg/day.

  Levetiracetam Oral Solution USP Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  Total daily dose (mL/day) = Daily dose (mg/kg/day) × patient weight (kg) 100 mg/mL 2.3 Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy

  Initiate treatment with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase the dosage by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been studied.

  2.4 Dosing for Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years and Older

  Initiate treatment with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase dosage by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 to less than or equal to 16 Years

  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight less than or equal to 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)].

  2.5 Dosage Adjustments in Adult Patients with Renal Impairment

  Levetiracetam Oral Solution USP dosing must be individualized according to the patient's renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  CLcr=  [140-age (years)] × weight (kg) (× 0.85 for female patients) 72 × serum creatinine (mg/dL)

  Then CLcr is adjusted for body surface area (BSA) as follows:

  CLcr (mL/min/1.73m2)= CLcr (mL/min) × 1.73 BSA subject (m2) Table 1: Dosing Adjustment Regimen for Adult Patients with Renal Impairment Group Creatinine Clearance
  (mL/min/1.73m2) Dosage (mg) Frequency * Following dialysis, a 250 to 500 mg supplemental dose is recommended. Normal >80 500 to 1,500 Every 12 hours Mild 50–80 500 to 1,000 Every 12 hours Moderate 30–50 250 to 750 Every 12 hours Severe <30 250 to 500 Every 12 hours ESRD patients
  using dialysis ----- 500 to 1,000* Every 24 hours*

  Close
  No Recall

  More Info
• Vistapharm, Inc
  

  ×

  Levetiracetam Solution | Vistapharm, Inc

  

  ---

  Levetiracetam Oral Solution is indicated as adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

  Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.

  Partial Onset Seizures Adults 16 Years And Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose (see CLINICAL STUDIES), a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients Ages 4 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 52 mg/kg. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution.

  Levetiracetam Oral solution is given orally with or without food.

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients based on a daily dose of 20 mg/kg/day, 40 mg/kg/day or 60 mg/kg/day:

  Total daily dose (mL/day) =   Daily dose (mg/kg/day) × patient weight (kg) 100 mg/mL

  A household teaspoon or tablespoon is not an adequate measuring device. It is recommended that a calibrated measuring device be obtained and used. Healthcare providers should recommend a device that can measure and deliver the prescribed dose accurately, and provide instructions for measuring the dosage.

  Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  Adult Patients With Impaired Renal Function

  Levetiracetam Oral Solution dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 13. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the following formula:

  CLcr =   [140-age (years)] × weight (kg)   (× 0.85 for female patients) 72 × serum creatinine (mg/dL) Table 13: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function Group Creatinine Clearance
  (mL/min) Dosage
  (mg) Frequency * Following dialysis, a 250 to 500 mg supplement dose is recommended Normal >80 500 to 1,500 Every 12 h Mild 50 – 80 500 to 1,000 Every 12 h Moderate 30 – 50 250 to 750 Every 12 h Severe <30 250 to 500 Every 12 h ESRD patients using dialysis — 500 to 1,000 * Every 24 h

  Close
  No Recall

  More Info
• Golden State Medical Supply, Inc.
  

  ×

  Levetiracetam Solution | Golden State Medical Supply, Inc.

  

  ---

  Levetiracetam is indicated as adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

  Partial Onset Seizures Adults 16 Years and Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose (see CLINICAL STUDIES), a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients Ages 4 to < 16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 52 mg/kg. Patients with body weight ≤ 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution.

  Levetiracetam is given orally with or without food.

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients based on a daily dose of 20 mg/kg/day, 40 mg/kg/day or 60 mg/kg/day:

  Total daily dose (mL/day) = Daily dose (mg/kg/day) x patient weight (kg)

  100 mg/mL

  A household teaspoon or tablespoon is not an adequate measuring device. It is recommended that a calibrated measuring device be obtained and used. Healthcare providers should recommend a device that can measure and deliver the prescribed dose accurately, and provide instructions for measuring the dosage.

  Adult Patients with Impaired Renal Function

  Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 11. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the following formula:

                        [140-age (years)] × weight (kg)
  CLcr = —————————————————   (× 0.85 for female patients)
                         72 × serum creatinine (mg/dL)

  Table 9: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function Group Creatinine Clearance
  (mL/min) Dosage
  (mg) Frequency * Following dialysis, a 250 to 500 mg supplemental dose is recommended. Normal > 80 500 to 1,500 Every 12 h Mild 50 – 80 500 to 1,000 Every 12 h Moderate 30 – 50 250 to 750 Every 12 h Severe < 30 250 to 500 Every 12 h ESRD patients using dialysis ---- 500 to 1,000 *Every 24 h

  Close
  No Recall

  More Info
• Atlantic Biologicals Corps
  

  ×

  Levetiracetam Solution | Atlantic Biologicals Corps

  

  ---

  2.1 Important Administrations Instructions

  Levetiracetam oral solution is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Partial Onset Seizures Adults 16 Years And Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [ ], a consistent increase in response with increased dose has not been shown. see Clinical Studies ( ) 14.1

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients 1 Month To <6 Months

  Treatment should be initiated with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily). In the clinical trial, the mean daily dose was 35 mg/kg in this age group. The effectiveness of lower doses has not been studied.

  6 Months To <4 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 47 mg/kg in this age group.

  4 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  2.3 Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Primary Generalized Tonic-Clonic Seizures Adults 16 Years And Older

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [ ]. see Dosage and Administration ( ) 2.1

  2.5 Adult Patients With Impaired Renal Function

  Levetiracetam oral solution dosing must be individualized according to the patient’s renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this, an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  The CLcr is adjusted for body surface area (BSA) as follows:

  Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function Group Creatinine Clearance      (mL/min/1.73m )
  2 Dosage (mg)      Frequency Following dialysis, a 250 to 500 mg supplemental dose is recommended. 1 Normal >80 500 to 1,500 Every 12 hours Mild 50 - 80 500 to 1,000 Every 12 hours Moderate 30 - 50 250 to 750 Every 12 hours Severe <30 250 to 500 Every 12 hours ESRD patients using dialysis      ---- 500 to 1,000 1 Every 24 hours 1

  Close
  No Recall

  More Info
• Tris Pharma Inc
  

  ×

  Levetiracetam Solution | Tris Pharma Inc

  

  ---

  Use the oral solution for pediatric patients with body weight ≤ 20 kg (2.1). For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon) (2.1)

  1 Month To < 6 Months: 7 mg/kg twice daily, increase in increments of 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily (2.2) 6 Months To < 4 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily (2.2) 4 Years To < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.2) Adults 16 Years And Older: 500 mg twice daily, increase as needed and tolerated in increments of 500 mg twice daily every 2 weeks to a maximum recommended dose of 1500 mg twice daily (2.2)

  6 Years To < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily (2.4) Adults 16 Years And Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily (2.4) 2.1 Important Administration Instructions

  Levetiracetam oral solution is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Partial Onset Seizures

  Adults 16 Years And Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [see Clinical Studies (14.1)], a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients

  1 Month To < 6 Months

  Treatment should be initiated with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily). In the clinical trial, the mean daily dose was 35 mg/kg in this age group. The effectiveness of lower doses has not been studied.

  6 Months To <4 Years:

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased in 2 weeks by an increment of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 47 mg/kg in this age group.

  4 Years To < 16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of

  20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  Daily dose (mg/kg/day) x patient weight (kg) Total daily dose (mL/day) = ------------------------------------------ 100 mg/mL 2.3 Myoclonic Seizures In Patients 12 Years of Age and Older With Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years And Older

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)].

  2.5 Adult Patients With Impaired Renal Function

  Levetiracetam dosing must be individualized according to the patient’s renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient’s creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  [140-age (years)] x weight (kg)  (x 0.85 CLcr= --------------------------------------for female 72 x serum creatinine (mg/dL)   patients)

  Then CLcr is adjusted for body surface area (BSA) as follows:

  CLcr (mL/min) CLcr (mL/min/1.73m2)= --------------------------- x 1.73 BSA subject (m2)

  Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function

  Group Creatinine Clearance(mL/min/1.73m2) Dosage(mg) Frequency Normal > 80 500 to 1,500 Every 12 hours Mild 50 to 80 500 to 1,000 Every 12 hours Moderate 30 to 50 250 to 750 Every 12 hours Severe < 30 250 to 500 Every 12 hours ESRD patients using dialysis ---- 500 to 1,0001 Every 24 hours1 1 Following dialysis, a 250 to 500 mg supplemental dose is recommended.

  Close
  No Recall

  More Info
• Cypress Pharmaceutical, Inc.
  

  ×

  Levetiracetam Solution | Cypress Pharmaceutical, Inc.

  

  ---

  2.1 Important Administrations Instructions

  Levetiracetam oral solution is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Partial Onset Seizures Adults 16 Years And Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [see Clinical Studies (14.1)], a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients

  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.’s levetiracetam oral solution. However, due to UCB, Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  4 Years To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  2.3 Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Primary Generalized Tonic-Clonic Seizures Adults 16 Years And Older

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)].

  2.5 Adult Patients With Impaired Renal Function

  Levetiracetam oral solution dosing must be individualized according to the patient’s renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this, an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  Then CLcr is adjusted for body surface area (BSA) as follows:

  Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function Group Creatinine Clearance     
  (mL/min/1.73m2) Dosage (mg)      Frequency 1 Following dialysis, a 250 to 500 mg supplemental dose is recommended. Normal >80 500 to 1,500 Every 12 hours Mild 50 - 80 500 to 1,000 Every 12 hours Moderate 30 - 50 250 to 750 Every 12 hours Severe <30 250 to 500 Every 12 hours ESRD patients using dialysis      ---- 500 to 1,0001 Every 24 hours1

  Close
  No Recall

  More Info
• Mckesson Packaging Services A Business Unit Of Mckesson Corporation
  

  ×

  Levetiracetam Solution | Mckesson Packaging Services A Business Unit Of Mckesson Corporation

  

  ---

  Levetiracetam is indicated as adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

  Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.

  Levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.

  Partial  Onset  Seizures
  Adults 16 Years And Older
  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose (see CLINICAL STUDIES), a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients Ages 4 To < 16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 52 mg/kg.  Patients with body weight ≤ 20 kg should be dosed with oral solution.  Patients with body weight above 20 kg can be dosed with either tablets or oral solution.

  Levetiracetam is given orally with or without food.

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients based on a daily dose of 20 mg/kg/day, 40 mg/kg/day or 60 mg/kg/day:

  
  Total daily dose (mL/day) = Daily dose (mg/kg/day) x patient weight (kg)
  --------------------------------------------------                                       100 mg/mL

  A household teaspoon or tablespoon is not an adequate measuring device. It is recommended that a calibrated measuring device be obtained and used. Healthcare providers should recommend a device that can measure and deliver the prescribed dose accurately, and provide instructions for measuring the dosage.

  Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years And Older

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 To < 16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤ 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution.

  Adult Patients With Impaired Renal Function

  Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 15. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the following formula:

  
  CLcr = [140-age (years)] x weight (kg)
  --------------------------------------(x 0.85 for female patients) 72 x serum creatinine (mg/dL)

  Table 15: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function

  Group Creatinine Clearance
  (mL/min) Dosage
  (mg) Frequency 1 Following dialysis, a 250 to 500 mg supplemental dose is recommended. Normal > 80 500 to 1,500 Every 12 h Mild 50 to 80 500 to 1,000 Every 12 h Moderate 30 to 50 250 to 750 Every 12 h Severe < 30 250 to 500 Every 12 h ESRD patients using dialysis ---- 500 to 1,000 1Every 24 h

  Close
  No Recall

  More Info
• Llc Federal Solutions
  

  ×

  Levetiracetam Solution | Llc Federal Solutions

  

  ---

  DOSAGE AND ADMINISTRATION
  Levetiracetam Oral Solution is indicated as adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
  Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.
  Levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.
  Partial Onset Seizures
  Adults 16 Years And Older
  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose (see CLINICAL STUDIES), a consistent increase in response with increased dose has not been shown.
  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.
  Pediatric Patients Ages 4 To <16 Years
  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 52 mg/kg. Patients with body weight ≤ 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with oral solution.
  Levetiracetam Oral Solution is given orally with or without food.
  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients based on a daily dose of 20 mg/kg/day, 40 mg/kg/day or 60 mg/kg/day:
                                                Daily dose (mg/kg/day) x patient weight (kg)
  Total daily dose (mL/day) = ———————————————————————       
                                                                           100 mg/mL
  A household teaspoon or tablespoon is not an adequate measuring device. It is recommended that a calibrated measuring device be obtained and used. Healthcare providers should recommend a device that can measure and deliver the prescribed dose accurately, and provide instructions for measuring the dosage.
  Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy
  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.
  Primary Generalized Tonic-Clonic Seizures
  Adults 16 Years And Older
  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.
  Pediatric Patients Ages 6 To <16 Years
  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤ 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed oral solution.

  Adult Patients With Impaired Renal Function
  Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 15. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the following formula:
                [140-age (years)] x weight (kg)
  CLcr = —————————————————       (x 0.85 for female patients)
                   72 x serum creatinine (mg/dL)

  Table 15: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function Group Creatinine Clearance
  (mL/min) Dosage
  (mg) Frequency Normal > 80 500 to 1,500 Every 12 h Mild 50 – 80 500 to 1,000 Every 12 h Moderate 30 – 50 250 to 750 Every 12 h Severe <30 250 to 500 Every 12 h ESRD patients using dialysis ---- 500 to 1,000 1Every 24 h

  1 Following dialysis, a 250 to 500 mg supplemental dose is recommended.

  Close
  No Recall

  More Info
• Silarx Pharmaceuticals, Inc
  

  ×

  Levetiracetam Solution | Silarx Pharmaceuticals, Inc

  

  ---

  Levetiracetam Oral Solution is indicated as adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

  Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.

  Levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.

  Partial Onset Seizures

  Adults 16 Years And Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose (see CLINICAL STUDIES), a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients Ages 4 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 52 mg/kg. Patients with body weight ≤ 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with oral solution.

  Levetiracetam Oral Solution is given orally with or without food.

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients based on a daily dose of 20 mg/kg/day, 40 mg/kg/day or 60 mg/kg/day:

                                                Daily dose (mg/kg/day) x patient weight (kg)
  Total daily dose (mL/day) = ———————————————————————       
                                                                           100 mg/mL

  A household teaspoon or tablespoon is not an adequate measuring device. It is recommended that a calibrated measuring device be obtained and used. Healthcare providers should recommend a device that can measure and deliver the prescribed dose accurately, and provide instructions for measuring the dosage.

  Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy
  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years And Older
  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.
  
  Pediatric Patients Ages 6 To <16 Years
  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤ 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed oral solution.

  Adult Patients With Impaired Renal Function

  Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 15. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the following formula:
  

  
  

                [140-age (years)] x weight (kg)
  CLcr = —————————————————       (x 0.85 for female patients)
                   72 x serum creatinine (mg/dL)

  Table 15: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function Group Creatinine Clearance
  (mL/min) Dosage
  (mg) Frequency Normal > 80 500 to 1,500 Every 12 h Mild 50 – 80 500 to 1,000 Every 12 h Moderate 30 – 50 250 to 750 Every 12 h Severe <30 250 to 500 Every 12 h ESRD patients using dialysis ---- 500 to 1,000 1Every 24 h

  1 Following dialysis, a 250 to 500 mg supplemental dose is recommended.

  Close
  No Recall

  More Info
• Cardinal Health
  

  ×

  Levetiracetam Solution | Bluepoint Laboratories

  

  ---

  2.1 General Instructions for Use

  To minimize the risk of seizure, increase the dose gradually [see Warnings and Precautions (5.3)].

  Bupropion hydrochloride extended-release tablets (XL) should be swallowed whole and not crushed, divided, or chewed. Bupropion hydrochloride extended-release tablets (XL) should be administered in the morning and may be taken with or without food.

  2.2 Dosage for Major Depressive Disorder (MDD)

  The recommended starting dose for MDD is 150 mg once daily in the morning. After 4 days of dosing, the dose may be increased to the target dose of 300 mg once daily in the morning.

  It is generally agreed that acute episodes of depression require several months or longer of antidepressant treatment beyond the response in the acute episode. It is unknown whether the bupropion hydrochloride extended-release tablets (XL) dose needed for maintenance treatment is identical to the dose that provided an initial response. Periodically reassess the need for maintenance treatment and the appropriate dose for such treatment.

  2.3 Dosage for Seasonal Affective Disorder (SAD)

  The recommended starting dose for SAD is 150 mg once daily. After 7 days of dosing, the dose may be increased to the target dose of 300 mg once daily in the morning. Doses above 300 mg of bupropion hydrochloride extended-release were not assessed in the SAD trials.

  For the prevention of seasonal MDD episodes associated with SAD, initiate bupropion hydrochloride extended-release tablets (XL) in the autumn, prior to the onset of depressive symptoms. Continue treatment through the winter season. Taper and discontinue bupropion hydrochloride extended-release tablets (XL) in early spring. For patients treated with 300 mg per day, decrease the dose to 150 mg once daily before discontinuing bupropion hydrochloride extended-release tablets (XL). Individualize the timing of initiation and duration of treatment should be individualized, based on the patient's historical pattern of seasonal MDD episodes.

  2.4 Switching Patients from Bupropion Hydrochloride Tablets or from Bupropion Hydrochloride Sustained-Release Tablets

  When switching patients from bupropion hydrochloride tablets to bupropion hydrochloride extended-release tablets (XL) or from bupropion hydrochloride sustained-release tablets to bupropion hydrochloride extended-release tablets (XL), give the same total daily dose when possible.

  2.5 To Discontinue Bupropion Hydrochloride Extended-Release Tablets (XL), Taper the Dose

  When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation.

  2.6 Dosage Adjustment in Patients with Hepatic Impairment

  In patients with moderate to severe hepatic impairment (Child-Pugh score: 7 to 15), the maximum dose is 150 mg every other day. In patients with mild hepatic impairment (Child-Pugh score: 5 to 6), consider reducing the dose and/or frequency of dosing [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. 

  2.7 Dose Adjustment in Patients with Renal Impairment

  Consider reducing the dose and/or frequency of bupropion hydrochloride extended-release tablets (XL) in patients with renal impairment (Glomerular Filtration Rate < 90 mL/min) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

  2.8 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Antidepressant

  At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with bupropion hydrochloride extended-release tablets (XL). Conversely, at least 14 days should be allowed after stopping bupropion hydrochloride extended-release tablets (XL) before starting an MAOI antidepressant [see Contraindications (4) and Drug Interactions (7.6)].

  2.9 Use of Bupropion Hydrochloride Extended-Release Tablets (XL) with Reversible MAOIs Such as Linezolid or Methylene Blue

  Do not start bupropion hydrochloride extended-release tablets (XL) in a patient who is being treated with a reversible MAOI such as linezolid or intravenous methylene blue. Drug interactions can increase risk of hypertensive reactions. In a patient who requires more urgent treatment of a psychiatric condition, non-pharmacological interventions, including hospitalization, should be considered [see Contraindications (4)].

  In some cases, a patient already receiving therapy with bupropion hydrochloride extended-release tablets (XL) may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of hypertensive reactions in a particular patient, bupropion hydrochloride extended-release tablets (XL) should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for 2 weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with bupropion hydrochloride extended-release tablets (XL) may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue.

  The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with bupropion hydrochloride extended-release tablets (XL) is unclear. The clinician should, nevertheless, be aware of the possibility of a drug interaction with such use [see Contraindications (4) and Drug Interactions (7.6)].

  Close
  No Recall

  More Info
• Morton Grove Pharmaceuticals, Inc.
  

  ×

  Levetiracetam Solution | Morton Grove Pharmaceuticals, Inc.

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Dosing for Partial Onset Seizures

  Adults 16 Years and Older

  Initiate treatment with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients

  1 Month to < 6 Months

  Initiate treatment with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily). In the clinical trial, the mean daily dose was 35 mg/kg in this age group. The effectiveness of lower doses has not been studied.

  6 Months to <4 Years:

  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose in 2 weeks by an increment of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 47 mg/kg in this age group.

  4 Years to < 16 Years

  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  Total daily dose (mL/day) = Daily dose (mg/kg/day) × patient weight (kg) 100 mg/mL 2.3 Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy

  Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase the dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Dosing for Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years and Older

  Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 to <16 Years

  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)]. Only whole tablets should be administered.

  2.5 Dosage Adjustments in Adult Patients with Renal Impairment

  Levetiracetam oral solution dosing must be individualized according to the patient's renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  CLcr = [140-age (years)] × weight (kg) (× 0.85 for female patients) 72 × serum creatinine (mg/dL)

  Then CLcr is adjusted for body surface area (BSA) as follows:

  CLcr (mL/min/1.73m2) = CLcr (mL/min) × 1.73 BSA subject (m2) Table 1: Dosing Adjustment Regimen For Adult Patients with Renal Impairment Group Creatinine Clearance
  (mL/min/1.73m2) Dosage (mg) Frequency * Following dialysis, a 250 to 500 mg supplemental dose is recommended. Normal > 80 500 to 1,500 Every 12 hours Mild 50 – 80 500 to 1,000 Every 12 hours Moderate 30 – 50 250 to 750 Every 12 hours Severe < 30 250 to 500 Every 12 hours ESRD patients using dialysis —— 500 to 1,000* Every 24 hours*

  Close
  No Recall

  More Info
• Pharmaceutical Associates, Inc.
  

  ×

  Levetiracetam Solution | Pharmaceutical Associates, Inc.

  

  ---

  Levetiracetam oral solution is indicated as adjunctive treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

  Levetiracetam oral solution is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.

  Partial Onset Seizures Adults 16 Years And Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing, were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose (see CLINICAL STUDIES), a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients Ages 4 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg BID). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg BID). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 52 mg/kg. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution. Table 13 below provides a guideline for dosing based on weight during titration to 60 mg/kg/day.

  Levetiracetam is given orally with or without food.

  Table 13: Levetiracetam Oral Solution Weight-Based Dosing Guide For Children Patient Weight Daily Dose 20 mg/kg/day
  (BID dosing) 40 mg/kg/day
  (BID dosing) 60 mg/kg/day
  (BID dosing) 20.1-40 kg 500 mg/day
  2.5 mL
  BID 1000 mg/day
  5 mL
  BID 1500 mg/day
  7.5 mL
  BID >40 kg 1000 mg/day
  5 mL
  BID 2000 mg/day
  10 mL
  BID 3000 mg/day
  15 mL
  BID

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients based on a daily dose of 20 mg/kg/day, 40 mg/kg/day or 60 mg/kg/day:

  Total daily dose (mL/day) = Daily dose (mg/kg/day) × patient weight (kg) 100 mg/mL

  A household teaspoon or tablespoon is not an adequate measuring device. It is recommended that a calibrated measuring device be obtained and used. Healthcare providers should recommend a device that can measure and deliver the prescribed dose accurately, and provide instructions for measuring the dosage.

  Myoclonic Seizures In Patients 12 Years Of Age And Older With Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  Adult Patients With Impaired Renal Function

  Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 14. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in mL/min is needed. CLcr in mL/min may be estimated from serum creatinine (mg/dL) determination using the following formula:

  CLcr = [140-age (years)] × weight (kg) (× 0.85 for female patients) 72 × serum creatinine (mg/dL) Table 14: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function Group Creatinine Clearance
  (mL/min) Dosage
  (mg) Frequency * Following dialysis, a 250 to 500 mg supplemental dose is recommended. Normal >80 500 to 1,500 Every 12 h Mild 50 to 80 500 to 1,000 Every 12 h Moderate 30 to 50 250 to 750 Every 12 h Severe <30 250 to 500 Every 12 h ESRD patients using dialysis ---- 500 to 1,000 *Every 24 h

  Close
  No Recall

  More Info
• Qualitest Pharmaceuticals
  

  ×

  Levetiracetam Solution | Qualitest Pharmaceuticals

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam oral solution is given orally with or without food. The levetiracetam oral solution dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Dosing For Partial Onset Seizures

  Adults 16 Years And Older
  Initiate treatment with a daily dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily).  Additional dosing increments may be given (1,000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3,000 mg. There is no evidence that doses greater than 3,000 mg/day confer additional benefit.

  Pediatric Patients
  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.’s levetiracetam tablets and oral solution. However, due to UCB, Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  4 Years To < 16 Years
  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3,000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  2.3 Dosing For Myoclonic Seizures In Patients 12 Years of Age and Older With Juvenile Myoclonic Epilepsy

  Initiate treatment with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase the dosage by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been studied.

  2.4 Dosing For Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years And Older
  Initiate treatment with a dose of 1,000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase the dosage by 1,000 mg/day every 2 weeks to the recommended daily dose of 3,000 mg. The effectiveness of doses lower than 3,000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 To < 16 Years
  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤ 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)].

  2.5 Dosage Adjustments In Adult Patients With Renal Impairment

  Levetiracetam oral solution dosing must be individualized according to the patient’s renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient’s creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  Then CLcr is adjusted for body surface area (BSA) as follows:

  Table 1: Dosing Adjustment Regimen For Adult Patients With Renal Impairment * Following dialysis, a 250 to 500 mg supplemental dose is recommended. Group  Creatinine Clearance
  (mL/min/1.73m2)  Dosage (mg)  Frequency  Normal  > 80  500 to 1,500  Every 12 hours  Mild  50 to 80  500 to 1,000  Every 12 hours  Moderate  30 to 50  250 to 750  Every 12 hours  Severe  < 30  250 to 500  Every 12 hours  ESRD patients using dialysis  ----  500 to 1,000*  Every 24 hours*  

  Close
  No Recall

  More Info
• Actavis Mid Atlantic Llc
  

  ×

  Levetiracetam Solution | Actavis Mid Atlantic Llc

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form (oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight less than or equal to 20 kg. Prescribe the oral solution for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Partial Onset Seizures

  Adults 16 Years and Older
  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [see Clinical Studies (14.1)], a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients
  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.’s levetiracetam oral solution. However, due to UCB, Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  4 Years to less than 16 Years
  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  2.3 Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years and Older
  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 to less than 16 Years
  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight less than or equal to 20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)].

  2.5 Adult Patients with Impaired Renal Function

  Levetiracetam dosing must be individualized according to the patient’s renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient’s creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  Then CLcr is adjusted for body surface area (BSA) as follows:

  Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function  Group   Creatinine Clearance    Dosage (mg)     Frequency      (mL/min/1.73m2)      1Following dialysis, a 250 to 500 mg supplemental dose is recommended  Normal  > 80  500 to 1,500  Every 12 hours  Mild  50 – 80  500 to 1,000  Every 12 hours  Moderate  30 – 50  250 to 750  Every 12 hours  Severe  < 30  250 to 500  Every 12 hours  ESRD patients using dialysis    –  500 to 1,0001  Every 24 hours1

  Close
  No Recall

  More Info
• Lupin Pharmaceuticals, Inc.
  

  ×

  Levetiracetam Solution | B. Braun Medical Inc.

  

  ---

  2.1 Dosage for Treatment of Indicated Infections in Adults

  Cefazolin for Injection USP and Dextrose Injection USP in the DUPLEX® Container should be used only in patients who require the entire 1 or 2 gram dose and not any fraction thereof. The recommended adult dosages are outlined in Table 1. Cefazolin for Injection USP and Dextrose Injection USP should be administered intravenously (IV) over approximately 30 minutes.

  * In rare instances, doses of up to 12 grams of cefazolin per day have been used.   Table 1: Recommended Dosing Schedule in Adult Patients with CrCl Greater Than or Equal To 55 mL/min.   Site and Type of Infection   Dose   Frequency   Moderate to severe infections   500 mg to 1 gram   every 6 to 8 hours   Mild infections caused by susceptible gram-positive cocci   250 mg to 500 mg   every 8 hours   Acute, uncomplicated urinary tract infections   1 gram   every 12 hours   Pneumococcal pneumonia   500 mg   every 12 hours   Severe, life-threatening infections (e.g., endocarditis, septicemia)*     1 gram to 1.5 grams   every 6 hours 2.2 Dosage for Perioperative Prophylactic Use in Adults

  To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are:

  1 to 2 gram IV administered 1/2 hour to 1 hour prior to the start of surgery. For lengthy operative procedures (e.g., 2 hours or more), 500 mg to 1 gram IV during surgery (administration modified depending on the duration of the operative procedure). 500 mg to 1 gram IV every 6 to 8 hours for 24 hours postoperatively.

  It is important that (i) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibacterial concentrations are present in the serum and tissues at the time of initial surgical incision; and (ii) cefazolin be administered, if necessary, at appropriate intervals during surgery to provide sufficient concentrations of the antibacterial drug at the anticipated moments of greatest exposure to infective organisms. 

  The prophylactic administration of cefazolin should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of cefazolin may be continued for 3 to 5 days following the completion of surgery.

  2.3 Dosage in Pediatric Patients

  The 2 grams dose of Cefazolin for Injection USP and Dextrose Injection USP is not recommended for use in pediatric patients.

  Only administer 1 gram Cefazolin for Injection USP and Dextrose Injection USP to pediatric patients where the individual dose is the entire contents of the 1g DUPLEX® container and not any fraction of it.

  Recommended doses for pediatric patients are as follows:

  For most mild to moderately severe infections: a total daily dosage of 25 to 50 mg per kg of body weight, divided into 3 or 4 equal doses.  For severe infections, the total daily dosage may be increased to 100 mg per kg of body weight.

  There are no dosage recommendations for pediatric patients for perioperative prophylaxis or for pediatric patients with renal impairment.

  2.4 Dosage in Adult Patients with Renal Impairment

  Cefazolin may be used in patients with renal impairment with the dosage adjustments outlined in Table 2. All reduced dosage recommendations apply after an initial loading dose appropriate to the severity of the infection.

    Table 2: Dosage Adjustment for Patients with Renal Impairment   Creatinine Clearance   Dose   Frequency   55 mL/min. or greater   full dose   normal frequency   35 to 54 mL/min.   full dose   every 8 hours or longer   11 to 34 mL/min.   1/2 usual dose   every 12 hours   10 mL/min. or less   1/2 usual dose   every 18 to 24 hours 2.5 Preparation for Use of Cefazolin for Injection USP and Dextrose Injection USP in DUPLEX® Container

  This reconstituted solution is for intravenous use only.

  Do not use plastic containers in series connections. Such use would result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete. If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result.

  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Use only if solution is clear and container and seals are intact.

  DUPLEX® Container Storage

  To avoid inadvertent activation, the DUPLEX® Container should remain in the folded position until activation is intended.

  Patient Labeling and Drug Powder/Diluent Inspection

  Apply patient-specific label on foil side of container. Use care to avoid activation. Do not cover any portion of foil strip with patient label. Unlatch side tab and unfold DUPLEX® Container (see Diagram 1). Visually inspect diluent chamber for particulate matter. Use only if container and seals are intact. To inspect the drug powder for foreign matter or discoloration, peel foil strip from drug chamber (see Diagram 2). Protect from light after removal of foil strip.

  Note: If foil strip is removed, the container should be re-folded and the side tab latched until ready to activate. The product must then be used within 7 days, but not beyond the labeled expiration date.

  Reconstitution (Activation)

  Do not use directly after storage by refrigeration, allow the product to equilibrate to room temperature before patient use. Unfold the DUPLEX® container and point the set port in a downward direction. Starting at the hanger tab end, fold the DUPLEX® Container just below the diluent meniscus trapping all air above the fold. To activate, squeeze the folded diluent chamber until the seal between the diluent and powder opens, releasing diluent into the drug powder chamber (see Diagram 3). Agitate the liquid-powder mixture until the drug powder is completely dissolved.

  Note: Following reconstitution (activation), product must be used within 24 hours if stored at room temperature or within 7 days if stored under refrigeration.

  Administration

  Visually inspect the reconstituted solution for particulate matter. Point the set port in a downwards direction. Starting at the hanger tab end, fold the DUPLEX® Container just below the solution meniscus trapping all air above the fold. Squeeze the folded DUPLEX® Container until the seal between reconstituted drug solution and set port opens, releasing liquid to set port (see Diagram 4). Prior to attaching the IV set, check for minute leaks by squeezing container firmly. If leaks are found, discard container and solution as sterility may be compromised. Using aseptic technique, peel foil cover from the set port and attach sterile administration set (see Diagram 5). Refer to directions for use accompanying the administration set.

  Important Administration Instructions

  Do not use in series connections. Do not introduce additives into the DUPLEX® Container. Administer Cefazolin for Injection USP and Dextrose Injection USP intravenously over approximately 30 minutes.

  Close
  No Recall

  More Info
• Sandoz Inc.
  

  ×

  Levetiracetam Solution | Sandoz Inc.

  

  ---

  2.1  Important Administration Instructions

  Levetiracetam oral solution USP, 100 mg/mL is given orally with or without food. The levetiracetam oral solution USP, 100 mg/mL dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg.
  Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2  Partial Onset Seizures

  Adults 16 Years and Older
  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [see Clinical Studies (14.1)], a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients
  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.’s levetiracetam tablets and oral solution. However, due to UCB, Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  4 Years to < 16 Years
  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced.  In the clinical efficacy trial, the mean daily dose was 44 mg/kg.  The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution USP, 100 mg/mL Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  Daily dose (mg/kg/day) x patient weight (kg) Total daily dose (mL/day) = ---------------------------------------------------------------- 100 mg/mL 2.3  Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4  Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years and Older
  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6  to <16 Years
  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)].  Only whole tablets should be administered.

  2.5  Adult Patients with Impaired Renal Function

  Levetiracetam oral solution USP, 100 mg/mL dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  
                [140-age (years)] x weight (kg)
  CLcr = --------------------------------------------- (x 0.85 for female patients)
                   72 x serum creatinine (mg/dL)

  Then CLcr is adjusted for body surface area (BSA) as follows:
                                              CLcr (mL/min)
  CLcr (mL/min/1.73m2) =---------------------------- x 1.73
                                             BSA subject (m2)

  Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function

  Group Creatinine Clearance
  (mL/min/1.73m2) Dosage
  (mg) Frequency Normal > 80 500 to 1,500 Every 12 hours Mild 50 to 80 500 to 1,000 Every 12 hours Moderate 30 to 50 250 to 750 Every 12 hours Severe < 30 250 to 500 Every 12 hours ESRD patients using dialysis ---- 500 to 1,0001 Every 24 hours1

  1 Following dialysis, a 250 to 500 mg supplemental dose is recommended.

  Close
  No Recall

  More Info
• Breckenridge Pharmaceutical, Inc.
  

  ×

  Levetiracetam Solution | Breckenridge Pharmaceutical, Inc.

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam oral solution is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Partial Onset Seizures

  Adults 16 Years and Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [see Clinical Studies (14.1)], a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients

  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.'s levetiracetam oral solution. However, due to UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  4 Years to < 16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  Total daily dose (mL/day) =  Daily dose (mg/kg/day) × patient weight (kg)   100 mg/mL 2.3 Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years and Older

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 to <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)].

  2.5 Adult Patients with Impaired Renal Function

  Levetiracetam oral solution dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  CLcr=  [140-age (years)] × weight (kg)   (× 0.85 for female patients) 72 × serum creatinine (mg/dL)

  Then CLcr is adjusted for body surface area (BSA) as follows:

  CLcr (mL/min/1.73m2)=  CLcr (mL/min)  × 1.73 BSA subject (m2) Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function Group Creatinine Clearance (mL/min/1.73m2) Dosage (mg) Frequency * Following dialysis, a 250 to 500 mg supplemental dose is recommended. Normal > 80 500 to 1,500 Every 12 hours Mild 50 – 80 500 to 1,000 Every 12 hours Moderate 30 – 50 250 to 750 Every 12 hours Severe < 30 250 to 500 Every 12 hours ESRD patients using dialysis ---- 500 to 1,000*  Every 24 hours*

  Close
  No Recall

  More Info
• Amneal Pharmaceuticals Of New York, Llc
  

  ×

  Levetiracetam Solution | Amneal Pharmaceuticals Of New York, Llc

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam oral solution, USP is given orally with or without food. The levetiracetam oral solution, USP dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Dosing for Partial Onset Seizures

  Adults 16 Years and Older

  Initiate treatment with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients

  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.’s levetiracetam oral solution. However, due to UCB Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  4 Years to < 16 Years

  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution, USP Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

                                 Daily dose (mg/kg/day) x patient weight (kg)
  Total daily dose (mL/day) = ---------------------------------------
                                                            100 mg/mL

  2.3 Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy

  Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Dosing for Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years and Older

  Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 to <16 Years

  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)]. Only whole tablets should be administered.

  2.5 Dosage Adjustments in Adult Patients with Renal Impairment

  Levetiracetam oral solution, USP dosing must be individualized according to the patient’s renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient’s creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

             [140-age (years)] x weight (kg)        (x 0.85
  CLcr= -----------------------------------------      for female
              72 x serum creatinine (mg/dL)        patients)

  Then CLcr is adjusted for body surface area (BSA) as follows:

                                              CLcr (mL/min)
  CLcr (mL/min/1.73m2)=  ---------------------------- x 1.73
                                             BSA subject (m2)

  Table 1: Dosing Adjustment Regimen for Adult Patients with Renal Impairment   Group   Creatinine Clearance
  (mL/min/1.73m2)   Dosage (mg)   Frequency  1 Following dialysis, a 250 to 500 mg supplemental dose is recommended.  Normal  > 80  500 to 1,500  Every 12 hours  Mild  50 to 80  500 to 1,000  Every 12 hours  Moderate  30 to 50  250 to 750  Every 12 hours  Severe  < 30  250 to 500  Every 12 hours  ESRD patients
  using dialysis  ----  500 to 1,0001  Every 24 hours1

  Close
  No Recall

  More Info
• Roxane Laboratories, Inc
  

  ×

  Levetiracetam Solution | Roxane Laboratories, Inc

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam Oral Solution, USP is given orally with or without food. The Levetiracetam Oral Solution, USP dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon)

  2.2 Partial Onset Seizures

  Adults 16 Years And Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [see Clinical Studies (14.1)], a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients

  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.’s levetiracetam tablets and oral solution. However, due to UCB, Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  4 Years To < 16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  Total daily dose (mL/day) = Daily dose (mg/kg/day) x patient weight (kg)

  100 mg/mL

  2.3 Myoclonic Seizures In Patients 12 Years of Age and Older With Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years And Older

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)]. Only whole tablets should be administered.

  2.5 Adult Patients With Impaired Renal Function

  Levetiracetam Oral Solution, USP dosing must be individualized according to the patient’s renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient’s creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  CLcr =

  [140-age (years)] x weight (kg)

  (x 0.85 for female patients)

  72 x serum creatinine (mg/dL)

  CLcr (mL/min/1.73m2)= CLcr (mL/min) x BSA subject (m2)

  Then CLcr is adjusted for body surface area (BSA) as follows:

  CLcr (mL/min/1.73m2 )=

  CLcr (mL/min)

  x 1.73

    BSA subject (m 2) Then CLcr is adjusted for body surface area (BSA) as follows:

  CLcr (mL/min/1.73m2)= CLcr (mL/min) x BSA subject (m2)

  Table 1: Dosing Adjustment Regimen for Adult Patients With Impaired Renal Function * Following dialysis, a 250 to 500 mg supplemental dose is recommended.

  Group

  Creatinine Clearance (mL/min/1.73m2)

  Dosage (mg)

  Frequency

  Normal

  > 80

  500 to 1,500

  Every 12 hours

  Mild

  50 - 80

  500 to 1,000

  Every 12 hours

  Moderate

  30 - 50

  250 to 750

  Every 12 hours

  Severe

  < 30

  250 to 500

  Every 12 hours

  ESRD patients using dialysis

  ----

  500 to 1,000

  Every 24 hours* 

  Close
  No Recall

  More Info
• Atlantic Biologicals Corps
  

  ×

  Levetiracetam Solution | Atlantic Biologicals Corps

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam oral solution, USP is given orally with or without food. The levetiracetam oral solution, USP dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Partial Onset Seizures

  Adults 16 Years and Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [ ], a consistent increase in response with increased dose has not been shown. seeClinical Studies (14.1)

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients

  1 Month to < 6 Months

  Treatment should be initiated with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily). In the clinical trial, the mean daily dose was 35 mg/kg in this age group. The effectiveness of lower doses has not been studied.

  6 Months to <4 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased in 2 weeks by an increment of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 47 mg/kg in this age group.

  4 Years to < 16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

    Levetiracetam Oral Solution, USPWeight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  Daily dose (mg/kg/day) x patient weight (kg)

  Total daily dose (mL/day) = ---------------------------------------

  100 mg/mL

  2.3 Myoclonic Seizures in Patients 12 Years of Age and Older With Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years and Older

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 to <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [ ]. Only whole tablets should be administered. seeDosage and Administration (2.1)

  2.5 Adult Patients with Impaired Renal Function

  Levetiracetam oral solution, USP dosing must be individualized according to the patient’s renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient’s creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  [140-age (years)] x weight (kg)    (x 0.85

  CLcr= -----------------------------------------  for female

  72 x serum creatinine (mg/dL)     patients)

  Then CLcr is adjusted for body surface area (BSA) as follows:

  CLcr (mL/min)

  CLcr (mL/min/1.73m )=  ---------------------------- x 1.73 2

  BSA subject (m ) 2

  Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function   Group   Creatinine Clearance (mL/min/1.73m )
  2   Dosage (mg)   Frequency   Following dialysis, a 250 to 500 mg supplemental dose is recommended. 1  Normal  > 80  500 to 1,500  Every 12 hours  Mild  50 to 80  500 to 1,000  Every 12 hours  Moderate  30 to 50  250 to 750  Every 12 hours  Severe  < 30  250 to 500  Every 12 hours  ESRD patients using dialysis
   ----  500 to 1,000 1  Every 24 hours 1

  Close
  No Recall

  More Info
• Atlantic Biologicals Corps
  

  ×

  Levetiracetam Solution | Atlantic Biologicals Corps

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam oral solution is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form, and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Partial Onset Seizures

  Adults 16 Years And Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose , a consistent increase in response with increased dose has not been shown. [see ] Clinical Studies (14.1)

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients

  1 Month To < 6 Months

  Treatment should be initiated with a daily dose of 14 mg/kg in 2 divided doses (7 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 14 mg/kg to the recommended daily dose of 42 mg/kg (21 mg/kg twice daily). In the clinical trial, the mean daily dose was 35 mg/kg in this age group. The effectiveness of lower doses has not been studied.

  6 Months To <4 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased in 2 weeks by an increment of 20 mg/kg to the recommended daily dose of 50 mg/kg (25 mg/kg twice daily). If a patient cannot tolerate a daily dose of 50 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 47 mg/kg in this age group.

  4 Years To < 16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  Total daily dose (mL/day) =

  Daily dose (mg/kg/day) x patient weight (kg)

  ----------------------------------------------------

  100 mg/mL

  2.3 Myoclonic Seizures In Patients 12 Years of Age and Older With Juvenile Myoclonic Epilepsy

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years And Older

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤ 20 kg should be dosed with oral solution . [see ] Dosage and Administration (2.1)

  2.5 Adult Patients With Impaired Renal Function

  Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  CLcr =

  [140-age (years)] x weight (kg)

  ------------------------------------ 72 x serum creatinine (mg/dL)

  (x 0.85 for female patients)

  Then CLcr is adjusted for body surface area (BSA) as follows:

  CLcr (mL/min/1.73m ) = 2

  CLcr (mL/min)

  ------------------------------------ BSA subject (m ) 2

  x 1.73

  Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function

  * Following dialysis, a 250 to 500 mg supplemental dose is recommended. Group (mL/min/1.73m )

  Creatinine Clearance

  2 Dosage (mg) Frequency Normal > 80 500 to 1,500 Every 12 hours Mild 50 – 80 500 to 1,000 Every 12 hours Moderate 30 – 50 250 to 750 Every 12 hours Severe < 30 250 to 500 Every 12 hours ESRD Patients using dialysis ---- 500 to 1,000 * Every 24 hours   *

  Close
  No Recall

  More Info
• Aurobindo Pharma Limited
  

  ×

  Levetiracetam Solution | Ivax Pharmaceuticals, Inc.

  

  ---

  2.1 Starting Dose

  Adults: The recommended starting dosage of anagrelide capsules is 0.5 mg four times daily or 1 mg twice daily.

  Pediatric Patients: The recommended starting dosage of anagrelide capsules is 0.5 mg daily.

  2.2 Titration

  Continue the starting dose for at least one week and then titrate to reduce and maintain the platelet count below 600,000/μL, and ideally between 150,000/μL and 400,000/μL. The dose increment should not exceed 0.5 mg/day in any one week. Dosage should not exceed 10 mg/day or 2.5 mg in a single dose [see Warnings and Precautions (5)]. Most patients will experience an adequate response at a dose of 1.5 to 3 mg/day. Monitor platelet counts weekly during titration then monthly or as necessary.

  2.3 Dose Modifications for Hepatic Impairment

  In patients with moderate hepatic impairment (Child Pugh score 7 to 9) start anagrelide capsules therapy at a dose of 0.5 mg/day and monitor frequently for cardiovascular events [see Warnings and Precautions (5.1), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. Patients with moderate hepatic impairment who have tolerated anagrelide capsules therapy for one week may have their dose increased. The dose increase increment should not exceed 0.5 mg/day in any one week. Avoid use of anagrelide capsules in patients with severe hepatic impairment.

  2.4 Clinical Monitoring

  Anagrelide capsules therapy requires clinical monitoring, including complete blood counts, assessment of hepatic and renal function, and electrolytes.

  To prevent the occurrence of thrombocytopenia, monitor platelet counts every two days during the first week of treatment and at least weekly thereafter until the maintenance dosage is reached. Typically, platelet counts begin to respond within 7 to 14 days at the proper dosage. In the clinical trials, the time to complete response, defined as platelet count ≤ 600,000/μL, ranged from 4 to 12 weeks. In the event of dosage interruption or treatment withdrawal, the rebound in platelet count is variable, but platelet counts typically will start to rise within 4 days and return to baseline levels in one to two weeks, possibly rebounding above baseline values. Monitor platelet counts frequently.

  Close
  No Recall

  More Info
• Cardinal Health
  

  ×

  Levetiracetam Solution | Seroyal Usa

  

  ---

  Directions

  adults and children (12 years and older): take one to two teaspoons every four to six hours

  or as recommended by your healthcare practitioner.

  children (1-11 years): take 1/2 teaspoon two times daily or as recommended by your healthcare practitioner.

  infants (0-11 months): take 1/2 teaspoon once daily or as recommended by your healthcare practitioner.

  Close
  No Recall

  More Info
• Northstar Rx Llc
  

  ×

  Levetiracetam Solution | Northstar Rx Llc

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam oral solution is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form (tablets or oral solution), and renal function.

  
  

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg.  Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

  
  

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Dosing for Partial Onset Seizures

  Adults 16 Years and Older
  
  Initiate treatment with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. There is no evidence that doses greater than 3000 mg/day confer additional benefit.
  
  Pediatric Patients
  
  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.’s levetiracetam oral solution. However, due to UCB, Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
  
  4 Years to < 16 Years
  
  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 44 mg/kg.  The maximum daily dose was 3000 mg/day.
  
  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients
  
  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:
  
                                                        Daily dose (mg/kg/day) x patient weight (kg)
  Total daily dose (mL/day) =   -------------------------------------------------------------
  ­                                                                              100 mg/mL

  2.3 Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy

  Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase the dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been studied.

  2.4 Dosing for Primary Generalized Tonic-Clonic Seizures
  

  Adults 16 Years and Older
  
  Initiate treatment with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Increase dosage by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.
  
  Pediatric Patients Ages 6 to <16 Years
  
  Initiate treatment with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤20 kg should be dosed with oral solution. Patients with body weight above 20 kg can be dosed with either tablets or oral solution [see Dosage and Administration (2.1)].

  2.5 Dosage Adjustments in Adult Patients with Renal Impairment
  

  Levetiracetam oral solution dosing must be individualized according to the patient’s renal function status. Recommended dosage adjustments for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient’s creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:
  
               [140-age (years)] x weight (kg)
  CLcr = -----------------------------------------  (x 0.85 for female patients)
                72 x serum creatinine (mg/dL)

  
  
  
  

  Then CLcr is adjusted for body surface area (BSA) as follows:
  
                                                 CLcr (mL/min)
  CLcr (mL/min/1.73 m2) = -------------------------- x 1.73
                                               BSA subject (m2)

  
  Table 1: Dosing Adjustment Regimen for Adult Patients with Renal Impairment Group Creatinine Clearance (mL/min/1.73 m2) Dosage
  (mg) Frequency 1 Following dialysis, a 250 to 500 mg supplemental dose is recommended.
     Normal
  > 80
  500 to 1,500
  Every 12 hours
     Mild
  50 – 80
  500 to 1,000
  Every 12 hours
     Moderate
  30 – 50
  250 to 750
  Every 12 hours
     Severe
  < 30
  250 to 500
  Every 12 hours
     ESRD patients using dialysis
  ----
  500 to 1,0001
  Every 24 hours1
  

  Close
  No Recall

  More Info
• Hi-tech Pharmacal Co., Inc.
  

  ×

  Levetiracetam Solution | Hi-tech Pharmacal Co., Inc.

  

  ---

  2.1 Important Administration Instructions

  Levetiracetam oral solution is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form, and renal function.

  Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg.

  When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon).

  2.2 Partial Onset Seizures

  Adults 16 Years And Older

  In clinical trials, daily doses of 1000 mg, 2000 mg, and 3000 mg, given as twice-daily dosing were shown to be effective. Although in some studies there was a tendency toward greater response with higher dose [see Clinical Studies (14.1)], a consistent increase in response with increased dose has not been shown.

  Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open-label studies for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.

  Pediatric Patients

  Dosing information in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for UCB, Inc.'s levetiracetam oral solution. However, due to UCB, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

  4 Years To < 16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). If a patient cannot tolerate a daily dose of 60 mg/kg, the daily dose may be reduced. In the clinical efficacy trial, the mean daily dose was 44 mg/kg. The maximum daily dose was 3000 mg/day.

  Levetiracetam Oral Solution Weight-Based Dosing Calculation For Pediatric Patients

  The following calculation should be used to determine the appropriate daily dose of oral solution for pediatric patients:

  Total daily dose (mL/day) =

  Daily dose (mg/kg/day) x patient weight (kg)

  ------------------------------------------------

  100 mg/mL

  2.3 Myoclonic Seizure in Patients 12 Years of Age and Older With Juvenile Myoclonic Epilepsy 2.4 Primary Generalized Tonic-Clonic Seizures

  Adults 16 Years and Older

  Treatment should be initiated with a dose of 1000 mg/day, given as twice-daily dosing (500 mg twice daily). Dosage should be increased by 1000 mg/day every 2 weeks to the recommended daily dose of 3000 mg. The effectiveness of doses lower than 3000 mg/day has not been adequately studied.

  Pediatric Patients Ages 6 To <16 Years

  Treatment should be initiated with a daily dose of 20 mg/kg in 2 divided doses (10 mg/kg twice daily). The daily dose should be increased every 2 weeks by increments of 20 mg/kg to the recommended daily dose of 60 mg/kg (30 mg/kg twice daily). The effectiveness of doses lower than 60 mg/kg/day has not been adequately studied. Patients with body weight ≤ 20 kg should be dosed with oral solution [see Dosage and Administration (2.1)].

  2.5 Adult Patients With Impaired Renal Function

  Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended doses and adjustment for dose for adults are shown in Table 1. In order to calculate the dose recommended for patients with renal impairment, creatinine clearance adjusted for body surface area must be calculated. To do this an estimate of the patient's creatinine clearance (CLcr) in mL/min must first be calculated using the following formula:

  CLcr =

  [140-age (years)] x weight (kg)

  ------------------------------------
  72 x serum creatinine (mg/dL)

  (x 0.85 for female patients)

  Then CLcr is adjusted for body surface area (BSA) as follows:

  CLcr (mL/min/1.73m2) =

  CLcr (mL/min)

  ------------------------------------ BSA subject (m2)

  x 1.73

  Table 1: Dosing Adjustment Regimen For Adult Patients With Impaired Renal Function

  Group

  Creatinine Clearance

  (mL/min/1.73m2)

  Dosage (mg)

  Frequency

  Normal

  > 80

  500 to 1,500

  Every 12 hours

  Mild

  50 – 80

  500 to 1,000

  Every 12 hours

  Moderate

  30 – 50

  250 to 750

  Every 12 hours

  Severe

  < 30

  250 to 500

  Every 12 hours

  ESRD patients using dialysis

  ----

  500 to 1,0001

  Every 24 hours1

  Close
  No Recall

  More Info